# Influence of host factors and parasite biomass on the severity of imported Plasmodium falciparum malaria

Nicolas Argy, Eric Kendjo, Claire Augé-Courtoi, Sandrine Cojean, Jérôme Clain, Pascal Houzé, Marc Thellier, Veronique Hubert, Philippe Deloron, Sandrine Houzé

► To cite this version:

Nicolas Argy, Eric Kendjo, Claire Augé-Courtoi, Sandrine Cojean, Jérôme Clain, et al.. Influence of host factors and parasite biomass on the severity of imported Plasmodium falciparum malaria. PLoS ONE, 2017, 12 (4), pp.e0175328. 10.1371/journal.pone.0175328. hal-01526362

HAL Id: hal-01526362

https://hal.sorbonne-universite.fr/hal-01526362

Submitted on 23 May 2017

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH ARTICLE

# Influence of host factors and parasite biomass on the severity of imported *Plasmodium falciparum* malaria

Nicolas Argy¹,²,³,⁴*, Eric Kendjo², Claire Augé-Courtoi³,⁴, Sandrine Cojean², Jérôme Clain²,³,⁴, Pascal Houzé³,⁵, Marc Thellier⁶,⁷, Veronique Hubert², Philippe Deloron³,⁴, Sandrine Houzé¹,²,³,⁴, for the CNRP study group¹

1 Laboratoire de parasitologie, hôpital Bichat-Claude Bernard, APHP, Paris, France, 2 Centre National de Référence du Paludisme, hôpital Bichat-Claude Bernard, APHP, Paris, France, 3 Faculté de Pharmacie, Université Paris Descartes, COMUE Sorbonne Paris Cité, Paris, France, 4 UMR MERIT 216, Institut de recherche pour le développement, Paris, France, 5 Laboratoire de pharmacologie, hôpital Saint-Louis, APHP, Paris, France, 6 Laboratoire de parasitologie, hôpital Pitié-Salpêtrière, APHP, Paris, France, 7 Faculté de Médecine, Université Pierre et Marie Curie, COMUE Sorbonne Paris Cité, Paris, France

¶ Membership of the Centre National de Référence du Paludisme (CNRP) study group is provided in the Acknowledgments.

* nicolas.argy@gmail.com

<figure><img src="image_2.png" /></figure>

<figure><img src="image_3.png" /></figure>

## OPEN ACCESS

**Citation:** Argy N, Kendjo E, Augé-Courtoi C, Cojean S, Clain J, Houzé P, et al. (2017) Influence of host factors and parasite biomass on the severity of imported *Plasmodium falciparum* malaria. PLoS ONE 12(4): e0175328. https://doi.org/10.1371/journal.pone.0175328

**Editor:** Luzia Helena Carvalho, Centro de Pesquisas Rene Rachou, BRAZIL

**Received:** January 12, 2017

**Accepted:** March 23, 2017

**Published:** April 14, 2017

**Copyright:** © 2017 Argy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** All the funding of support has been provided by Santé Publique France (https://www.santepubliquefrance.fr). This funding aims to support the Centre National de Référence du Paludisme in the exercise of their public health missions as the surveillance of imported malaria in metropolitan France and the malaria expertise diagnosis. The funder had no role in study design,

## Abstract

### Objectives

Imported malaria in France is characterized by various clinical manifestations observed in a heterogeneous population of patients such as travelers/expatriates and African migrants. In this population, host factors and parasite biomass associated with severe imported malaria are poorly known.

### Methods

From data collected by the Centre National de Référence du Paludisme, we identified epidemiological, demographic and biological features including parasite biomass and anti-plasmodial antibody levels (negative, positive and strongly positive serology) associated with different disease severity groups (very severe, moderately severe, and uncomplicated malaria) in 3 epidemiological groups (travelers/expatriates, first- and second-generation migrants).

### Results

Age, ethnicity, absence of prior infection with *P. falciparum*, antibody levels, plasma PfHRP2 levels, total and circulating parasite biomass were related to severe malaria onset. Sequestered parasite biomass tended to be increased in very severe malaria, and was strongly correlated to the antibody level of the host.
data collection and analysis, decision to publish, or
preparation of the manuscript.

**Competing interests:** The authors have declared
that no competing interests exist.

Conclusions

Prior exposure to *P. falciparum* is associated with high anti-plasmodial antibody levels which influence clinical presentation of imported malaria and its correlated circulating and sequestered parasite burden.

Introduction

*Plasmodium falciparum* infection in tropical regions also threatens non-endemic countries through imported cases [1]. Demographic, epidemiological and immunological features of malaria cases diagnosed in Metropolitan France (called imported malaria) are clearly different to those from malaria-endemic areas; the resulting severe forms of malaria are variable [2–5]. Severe malaria (SM) is the consequence of parasitized red blood cell (pRBC) sequestration, responsible for tissue hypoxia and endothelial barrier dysfunction in the microcirculation [6–9], resulting from cytoadherence via host endothelial receptors of extra-erythrocytic parasitic protein *Plasmodium falciparum* Erythrocyte Membrane Protein 1 (PfEMP1) [9–11]. In endemic areas, repeated exposure to *P. falciparum* antigens during childhood appears neces- sary to induce a non-sterilizing antibody-mediated response against antigenic variants of PfEMP1, preventing parasite sequestration in adults [12]. Because of the lack of or waning anti-malarial immunity, travelers and African migrants are at risk of SM [12].

Plasma concentrations of *P. falciparum* histidine-rich protein 2 (PfHRP2) have been evalu-
ated as a tool to improve the definition of SM in malaria-endemic areas [13–15]. Plasma
PfHRP2 levels, specifically produced by *P. falciparum* and released by schizonts, were reported
to better reflect the total parasite biomass, including the sequestered component, than periph-
eral blood parasite density [13, 14].

Various epidemiological risk factors have already been identified in severe imported
malaria [16–18]. However, the influences of host characteristics and parasite biomass on the
clinical presentation of imported malaria have not yet been investigated. Based on the clinical
description of cases [2, 3, 19], we aimed to identify demographic, epidemiological and biologi-
cal features associated with severe or non-severe imported malaria in France, including evalua-
tion of plasma PfHRP2 levels and parasite biomass.

**Materials and methods**

Ethics statement

No specific consent was required because of, in coordination with Santé Publique France organ-
nisation for the care and surveillance of malaria, the human clinical, epidemiological and bio-
logical data as well as parasitic biomarkers (parasitaemia, PfHRP2, total parasite biomass, total
circulating parasite biomass and sequestered parasite biomass) were collected in the CNRP
database and analysed in accordance with the common public health mission of all French
National Reference Centers (https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=
JORFTEXT000000810056&dateTexte=&categorieLien=id). The study of the biological sam-
ples obtained in the medical care context was considered as non-interventional research (arti-
cle L1221-1.1 of the French public health code) only requiring the non-opposition of the
patient during sampling (article L1211-2 of the French public health code). All data collected
were anonymized before analyse.
## Data sources and sample collection

This study was conducted in the Centre National de Référence du Paludisme (CNRP) laboratory, between 2010 and 2013. Prospective notification of imported malaria cases was undertaken through the CNRP national network of hospital laboratories. For each case, demographic (age, sex), epidemiological (ethnic origin, visited endemic area, self-reported prior exposure of malaria, immunosuppression, onset of symptoms, onset of diagnosis), biological (platelet counts, arterial blood pH, lactatemia, parasitemia, hemoglobin, creatinine, blood glucose, bilirubinemia) and clinical data (neurological and coagulation disorders, respiratory and renal failure, shock and jaundice) were collected in a database by the corresponding hospital, and the blood sample used for the initial parasitological diagnosis (D0 sample) was forwarded to the CNRP laboratory for diagnostic evaluation. Among these cases, inclusion criteria were as follows: patients not living in malaria-endemic countries and Caucasian expatriates infected with *P. falciparum*, D0 whole blood sample available in sufficient quantity to perform planned laboratory assays, no curative or preventive malaria treatment in the 30 days before diagnosis as confirmed by plasma determination of antimalarial drugs and metabolites at D0 (monodesethylchloroquine, chloroquine, cycloguanil, proguanil, quinine, doxycycline, sulfadoxine, pyrimethamine, mefloquine, lumefantrine, desbutyl-lumefantrine, amodiaquine, desethylamodiaquine, carboxymefloquine, atovaquine, piperaquine, primaquine and desbutylhalofantrine) and absence of bacterial co infection confirmed by negative blood culture during hospitalization.

## Laboratory procedures

*Plasmodium* species and parasite density were determined from D0 samples on stained blood films. Parasitemia was expressed as number of parasites per µL assuming a mean of 4,500,000 RBC/µL. In the event of low parasite density, DNA extraction and nested species-specific PCR [20, 21] were performed to confirm malaria diagnosis. D0 plasma samples were stored at -20°C and used for antimalarial drug testing, PfHRP2 assay and serologic testing.

## Study population

Patients were classified into 3 mutually exclusive groups: first-generation migrants (FGM) (born in malaria-endemic regions and living in Metropolitan France), second-generation migrants (SGM) (born in Metropolitan France from FGM parents and living in Metropolitan France), and travelers/expatriates (T/E). Travelers were born and living in non-malaria-endemic regions whereas expatriates were born in non-malaria-endemic regions and living in malaria-endemic regions. Malaria cases were classified into 2 groups: severe malaria (SM) defined according to the WHO definition [22], and uncomplicated malaria (UM) defined by the presence of asexual parasites and fever without any severity criteria. Following French recommendations regarding the classification of imported malaria cases [19], SM cases were also split into two sub-groups: very severe malaria (VSM), associated with a poor prognosis in the imported malaria context [19], defined by the presence of either organ dysfunction or shock or hyperlactatemia (or a combination of those) and moderately severe malaria (MSM), associated with a better prognosis [19], defined by the presence of one or several of the other WHO severity criteria.

## PfHRP2 enzyme-linked immunosorbent assay and estimation of total parasite biomass

PfHRP2 assays were performed with the Malaria Antigen Celisa® commercial kit (Cellabs®; Brookvale, Australia), as recommended by the manufacturer, on D0 plasma diluted in RPMI
1640 (Life Technologies®, Carlsbad, California, USA), according to the initial parasite density. PfHRP2 was quantified with the calibration curve obtained from three dilutions of the positive control. Samples with optical density values outside the range of the calibration were retested at an adapted dilution.

Total parasite biomass was estimated from the plasma PfHRP2 value, as described by Hen-
driksen et al. [15]. Total parasite biomass (Ptot) (number of parasites) was estimated by the
formula: Ptot = 7.3 x PfHRP2 (g/L) x (1-hematocrit (%)) x body weight (kg) x 10¹³. The esti-
mated total circulating parasite biomass (Pcirc) (number of parasites) was calculated as fol-
lows: Pcirc = parasites/µL x 10⁶ x blood volume (L). The blood volume was defined as 0.08 x
body weight (kg). The estimated sequestered parasite biomass (Pseq) corresponded to the dif-
ference between the estimated total parasite biomass and the estimated total circulating para-
site biomass such as Pseq (number of parasites) = Ptot (number of parasites)–Pcirc (number of
parasites) [15]. We assumed, as described in [15], that patients with negative Pseq values had
few or no sequestered parasites, and these negative values were considered 0.

Indirect immunofluorescence assay

Previous exposure to *Plasmodium sp.* was evaluated by the detection and the quantification of total antibodies against *Plasmodium falciparum*. IgG/A/M anti-plasmodial antibodies were detected and quantified by serological screening based on indirect immunofluorescence assay using whole schizonts of the 3D7 *P. falciparum* strain as crude antigens, and fluoresceine linked anti-human IgG/A/M (Biorad®; Hercules, California, USA) as conjugate. Quantification of plasmatic antibody concentration was estimated by serologic titers. A four-fold dilution series of plasma from 1:16 to 1:16,384 were performed to determine the titer of anti-plasmodial antibodies corresponding to the final dilution for which fluorescent signal remains positive. Slides were examined under blinded conditions by two experienced microscopists. In case of discordant result, a third microscopist observed in a blinded manner the slide to arbitrate. The validation of the method determined the threshold of positivity at a titer of (1:64) correspond-ing to the threshold with the best compromise between sensitivity and specificity for antibody detection. Antibody titers from (1:64) to (1:1024) are usually observed at malaria remission. Titers over or equal to (1:4096) are unusual. For statistical analysis, antibody titers were classi-fied into three groups: negative (or 0) corresponding to titers < 1:64; positive, corresponding to titers 1:64, 1:256 and 1:1024 and strongly positive, corresponding to titers ≥ 1:4096.

**Statistical analysis**

For each SM case included, control patients were randomly chosen from the pool of patients
with UM. Quantitative variables were represented by mean and standard deviation (SD) for
normal distributions, and by median and interquartile range [25th percentile-75th percentile]
for non-normal distributions. Categorical variables were evaluated according to size and fre-
quency. Quantitative variables with highly skewed distributions (plasma PfHRP2 concentra-
tion and parasite biomass values (Ptot, Pcirc and Pseq)) were log-transformed for statistical
analysis and graphic representation. Chi-square test and Fisher's exact test were used to com-
pare categorical variables between groups. ANOVA and Kruskall-Wallis tests were used to
compare quantitative variables between groups when appropriated. For all tests, a difference
was considered significant when p<0.05. All reported p values are two-tailed. Bonferroni's
correction was performed for multiple comparisons between quantitative variables and
groups.

The association between the presence of anti-plasmodial antibody as binary variable (posi-
tive/negative serology) and adjusted potential risk factors (theoretical and/or significant) as
disease severity sub-group (VSM, MSM, UM), epidemiological sub-group (FGM, SGM and T/E) and age as binary variable (age<18 years-old/age>18 years-old) was investigated using logistic regression. Secondly, the association between imported malaria onset and adjusted potential risk factors (theoretical and/or significant) as the categorical variable epidemiological sub-groups (FGM, SGM and T/E) and antibody levels as well as age, total, circulating and sequestered parasite biomass as continuous variable was also investigated by logistic regression. Four multiple linear regressions models were finally performed to identify influential factors of PfHRP2 and parasite biomass (Ptot, Pcirc and Pseq) as the continuous variable age, disease severity and epidemiological sub-groups and antibody levels. Significant positive or negative relationships between variables were expressed by the coefficient values. For regression models, two-way interaction terms between variables were tested, but none were significant. Statistical analyses were performed using STATA, version 12 (Stata corp®, College station, Texas, USA).

# Results

## Study population

Among the 333 *P. falciparum* imported malaria cases included in the study, 138 were severe malaria cases (41.4%) comprising 55 very severe malaria and 83 moderately severe malaria cases, and 195 were uncomplicated malaria cases (58.6%). Demographic, epidemiological, clinical and biological characteristics of the UM group and SM sub-groups are presented in Table 1. 215 patients were men (64.6%) and the mean age was 37.3±16.3 years. 215 patients were first-generation migrants (64.6%), 52 second-generation migrants (15.6%), and 66 travelers/expatriates (19.8%). Patients were infected in West Africa (68.5%), Central Africa (26.4%), East Africa (1.5%) and the Indian Ocean (3%).

Age of patients varied according to disease severity sub-groups ($p = 0.002$) (Table 1), with very severe malaria patients being older than moderately severe malaria and uncomplicated malaria patients ($p = 0.013$ and $p = 0.001$ respectively). The proportions of first-generation migrants, second-generation migrants and travelers/expatriates differed according to malaria severity ($p = 0.002$) (Table 1), the highest proportion of first-generation migrants and second-generation migrants was observed in the uncomplicated malaria group whereas travelers/expatriates were more common in the very severe malaria and moderately severe malaria groups. Previous self-reported history of malaria was more frequent in uncomplicated malaria than in very severe malaria and moderately severe malaria groups ($p = 0.03$) (Table 1). The median time between onset of symptoms and diagnosis differed between clinical sub-groups ($p = 0.04$), being higher in the very severe malaria group (4 days [2–6]) (Table 1). There was a gradual significant decrease in platelets related to disease severity decrease, from uncomplicated malaria to very severe malaria groups ($p < 0.01$). Median parasite density varied according to disease severity ($p < 0.001$) with parasite density being higher in severe malaria than in uncomplicated malaria ($p < 0.01$), but being similar in very severe malaria and moderately severe malaria groups.

## PfHRP2 and parasite biomass determination

To investigate parasite factors involved in severe malaria onset, plasma concentrations of PfHRP2 and total, circulating and sequestered parasite biomass were determined. Quantification of PfHRP2 was performed for 315 patients including 132 severe malaria cases (53 very severe malaria and 79 moderately severe malaria cases) and 183 uncomplicated malaria cases. The plasma levels of PfHRP2 were significantly higher in the very severe malaria and moderately severe malaria group compared to uncomplicated malaria (2766.9 ng/mL [772–5742.2])
<table><caption>Table 1. Demographic, epidemiological, clinical and biological data from imported malaria cases in Metropolitan France from 2010 to 2013.</caption><thead><tr><th rowspan="2"></th><th colspan="2">SM (n = 138)</th><th rowspan="2">UM (n = 195)</th><th rowspan="2">P value*</th></tr><tr><th>VSM (n = 55)</th><th>MSM (n = 83)</th></tr></thead><tbody><tr><td>Demographic data</td><td></td><td></td><td></td><td></td></tr><tr><td>Age (years)†</td><td>44.4 ±17</td><td>36.3 ±14.8</td><td>35.7 ±16.3</td><td>0.002<sup>a</sup></td></tr><tr><td>Men</td><td>36 (16.7)</td><td>51 (23.7)</td><td>128 (59.6)</td><td>0.8</td></tr><tr><td>Women</td><td>19 (16.1)</td><td>32 (27.1)</td><td>67 (56.8)</td><td></td></tr><tr><td>Epidemiological data</td><td></td><td></td><td></td><td></td></tr><tr><td>1<sup>st</sup> generation migrant</td><td>31 (14.4)</td><td>50 (23.2)</td><td>134 (62.3)</td><td>0.002</td></tr><tr><td>2<sup>nd</sup> generation migrant</td><td>5 (9.7)</td><td>11 (21.1)</td><td>36 (69.2)</td><td></td></tr><tr><td>Travelers/expatriates</td><td>19 (28.8)</td><td>22 (33.3)</td><td>25 (37.9)</td><td></td></tr><tr><td>Country of infection</td><td></td><td></td><td></td><td></td></tr><tr><td>West Africa</td><td>32 (14)</td><td>53 (23.2)</td><td>143 (62.8)</td><td>0.09</td></tr><tr><td>Central Africa</td><td>18 (20.4)</td><td>24 (27.3)</td><td>46 (52.3)</td><td></td></tr><tr><td>East Africa</td><td>1 (20)</td><td>1 (20)</td><td>3 (60)</td><td></td></tr><tr><td>Indian Ocean</td><td>3 (30)</td><td>4 (40)</td><td>3 (30)</td><td></td></tr><tr><td>Caribbean</td><td>0 (0)</td><td>1 (100)</td><td>0 (0)</td><td></td></tr><tr><td>Asia</td><td>1 (100)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>History of malaria§</td><td>8 (11.3)</td><td>13 (18.3)</td><td>50 (70.4)</td><td>0.03</td></tr><tr><td>Immunosuppression¶</td><td>6 (30)</td><td>7 (35)</td><td>7 (35)</td><td>0.06</td></tr><tr><td>Onset of symptoms (days)‡<sup>§</sup></td><td>3 [0–8]</td><td>3 [0–8]</td><td>3 [0–9]</td><td>0.28<sup>b</sup></td></tr><tr><td>Onset of diagnosis (days)‡<sup>§</sup> &amp;</td><td>4 [2–6]</td><td>3 [2–5]</td><td>3 [2–4]</td><td>0.04<sup>b</sup></td></tr><tr><td>Clinical data</td><td></td><td></td><td></td><td></td></tr><tr><td>Neurological disorders<sup>+</sup></td><td>30 (55)</td><td>0 (0)</td><td>0 (0)</td><td>NA</td></tr><tr><td>Coma</td><td>1 (2)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Shock</td><td>17 (31)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Respiratory failure</td><td>7 (13)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Hemorrhagic syndrome</td><td>1 (2)</td><td>1 (1)</td><td>0 (0)</td><td></td></tr><tr><td>Hemoglobinuria</td><td>4 (7)</td><td>7 (9)</td><td>0 (0)</td><td></td></tr><tr><td>Jaundice</td><td>19 (35)</td><td>12 (15)</td><td>0 (0)</td><td></td></tr><tr><td>Biological data</td><td></td><td></td><td></td><td></td></tr><tr><td>Platelets (Giga/L)‡</td><td>37 [21–69]</td><td>66 [42–108]</td><td>96 [64–142]</td><td>0.0001<sup>b</sup></td></tr><tr><td>Parasitemia (10<sup>3</sup>*parasites/µL)‡</td><td>360 [135–720]</td><td>270 [180–450]</td><td>45 [18–72]</td><td>0.0001<sup>b</sup></td></tr><tr><td>Acidosis (pH&lt;7.35)</td><td>7 (13)</td><td>0 (0)</td><td>0 (0)</td><td>NA</td></tr><tr><td>Lactacidemia (&gt;2.2 mmol/L)</td><td>27 (31)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Hyperparasitemia (&gt;180.000 parasites/µL)</td><td>40 (73)</td><td>65 (79)</td><td>0 (0)</td><td></td></tr><tr><td>Anemia (Hb&lt;8 g/dL)</td><td>3 (5)</td><td>4 (5)</td><td>0 (0)</td><td></td></tr><tr><td>Creatinine (&gt;265 µmol/L)</td><td>15 (27)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Blood glucose (&lt;2.2 mmol/L)</td><td>2 (4)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Bilirubinemia (&gt;50µmol/L)</td><td>24 (44)</td><td>14 (58)</td><td>0 (0)</td><td></td></tr></tbody></table>

SM, severe malaria; VSM, very severe malaria; MSM, moderately severe malaria; UM, uncomplicated malaria; Hb, hemoglobin; NA, not applicable. Categorical data are presented as absolute numbers (%).

* Chi-square test and Fisher's exact test were used to compare categorical variables between groups. Significant difference when p<0.05.

† Normally distributed variables are represented by their mean ± standard deviation.

a ANOVA was used to compare parametrics quantitative variables between groups. Significant difference when p<0.05.

b Existence of a prior self-reported malaria infection.

c Immunosuppressive status includes HIV infection (95%) and iatrogenic immunosuppression (5%).

d Non-normally distributed data are shown as median [25<sup>th</sup> percentile-75<sup>th</sup> percentile].

e Kruskall-Wallis tests was used to compare non-parametrics quantitative variables between groups. Significant difference when p<0.05.

f The onset of symptoms is the number of days between the return from endemic regions and the onset of clinical symptoms.

g The onset of diagnosis is the number of days between the onset of symptoms and the diagnosis in hospital. In our cohort, treatment started on the day of diagnosis.

h Neurological disorders included obnubilation, confusion, drowsiness and prostration [19].
and 1017 ng/mL [336.4–2908.9] respectively vs. 234.7 ng/mL [85–774.2]; p<0.001), but were similar in very severe malaria and moderately severe malaria groups (Fig 1A). Total (Ptot), circulating (Pcirc), and sequestered (Pseq) parasite biomass were estimated for the 176 patients for whom weight and hematocrit data were available, including 85 severe malaria cases (37 very severe malaria and 48 moderately severe malaria) and 91 uncomplicated malaria patients. Negative Pseq values were obtained in 35 patients (19.9%) and were reported as 0 [14, 15] (Fig 1B). Total and circulating parasite biomass varied according to disease severity. Significantly higher levels of both Ptot and Pcirc were observed in very severe malaria compared to uncomplicated malaria and in moderately severe malaria compared to uncomplicated malaria (Ptot: 1.2 X 10¹³ [2.8 X 10¹²–2.5 X 10¹³] in very severe malaria, 4.4 X 10¹² [1.5 X 10¹²–1.1 X 10¹³] in moderately severe malaria and 7.9 X 10¹¹ [3 X 10¹¹–2.3 X 10¹²] in uncomplicated malaria, p<0.001 for both comparisons; Pcirc: 2 X 10¹² [1 X 10¹²–4.2 X 10¹²] in very severe malaria, 1.5 X 10¹² [9.9 X 10¹¹–2.3 X 10¹²] in moderately severe malaria and 2.5 X 10¹¹ [1.0 X 10¹¹–3.5 X 10¹¹] in uncomplicated malaria, p<0.001 for both comparisons), but were similar in very severe malaria and moderately severe malaria groups (Fig 1B). Unexpectedly, Pseq levels did not differ between disease severity sub-groups.

## Anti-plasmodial antibody in plasma

Anti-plasmodial antibody levels in plasma were investigated as host factors potentially influencing clinical presentation of imported malaria. The variation in antibody levels was evaluated according to disease severity and epidemiological groups. The titers of total anti-P. falciparum plasma antibodies at D0 were determined for 329 patients, and classified as negative in 93 cases (28.3%), positive in 179 cases (54.4%), and strongly positive in 57 cases (17.3%). Antibody levels differed according to disease severity sub-groups (p = 0.023), negative antibody levels were more frequent in moderately severe malaria compared to uncomplicated malaria (41.5% vs. 22.9%; p = 0.003). Antibody levels also varied with regard to malaria exposure (p<0.001). Negative serology was less frequent in the first-generation migrants group (p<0.001) (Table 2).

In multivariate analysis, positive antibody titers were more likely observed in uncomplicated malaria (odds ratio [95% CI]: 2.2 [1.2–4]; p = 0.008). Negative antibody levels were more likely observed in second-generation migrants and travelers/expatriates groups (0.3 [0.1–0.6]; p = 0.002 and 0.3 [0.2–0.5]; p<0.001 respectively) (Table 3).

## Risk factors for clinical severity

Logistic regression was performed to identify risk factors for severe imported malaria onset from age, ethnic origin, antibody levels, and parasite biomass (S1–S4 Tables). This multivariate analysis identified, PfHRP2, Ptot and Pcirc as risk factors of MSM (odds ratio [95% CI]: 1.3 [1.2–1.6]; 1.3 [1.1–1.6], and 2.7 [1.9–3.9] respectively; all p<0.01) (S3 Table), and of VSM (1.6 [1.3–2.0]; 1.5 [1.2–1.9], and 2.1 [1.5–2.9], respectively; all p<0.01) (S2 Table). Conversely, decreased PfHRP2, Ptot and Pcirc were associated to uncomplicated malaria (0.5 [0.5–0.6]; 0.5 [0.4–0.7] and 0.1 [0.1–0.3] respectively; all p<0.01) (S4 Table). Depending on the statistical model, age was also a significant influent factor of very severe and moderately severe malaria onset (1 [1–1.1]; p = 0.01 and 1 [0.2–1]; p = 0.006 respectively) (S2 and S3 Tables) as well as positive serology sub-groups for moderately severe malaria and uncomplicated malaria (0.2 [0.1–0.7]; p = 0.01 and 4.4 [1.2–16.6]; p = 0.03 respectively) (S3 and S4 Tables).

Linear regression was performed to identify variables influencing PfHRP2 and parasite biomass values considered as risk factors of severity, from significant variables previously identified between disease severity sub-groups (VSM, MSM and UM) and from theoretical variables
<figure><img src="image_4.png" /></figure>

<figure><img src="image_5.png" /><figcaption>**Fig 1. PfHRP2 plasma levels and parasite biomass according to clinical presentation of imported malaria.** (A) Log-transformed plasma levels of PfHRP2 in the very severe malaria (VSM), moderately severe malaria (MSM) and uncomplicated malaria (UM) sub-groups. Levels of PfHRP2 were determined on 315 D0 plasma samples by ELISA. (*) corresponds to a significant difference using ANOVA test (p<0.05) and Bonferroni's correction (p<0.016). (B) Log-transformed estimated total parasite biomass (Ptot), estimated total circulating parasite biomass (Pcirc) and estimated sequestrated parasite biomass (Pseq) respectively in the very severe malaria (VSM) (red box plot), moderately severe malaria (MSM) (orange box plot) and uncomplicated malaria (UM) groups (white box plot). Parasite biomass was</figcaption></figure>
estimated for 176 patients using a mathematical approach as described [15] with quantitative plasma levels of PfHRP2 (g/ L) determined by ELISA, hematocrit (%), patient body weight (kg) and parasitemia (parasites/µL) on D0 sample. Box plot represents the median [25th percentile-75th percentile] with the extreme value 10th and 90th percentile. (*) corresponds to a significant difference using ANOVA test (p<0.05) and Bonferroni's correction (p<0.016).

https://doi.org/10.1371/journal.pone.0175328.g001

(age, epidemiological and antibody titer sub-groups) (Table 4). A negative correlation was observed between the UM group and PfHRP2, Ptot or Pcirc (coefficient [95% CI]: -1 [-2.1 - -1.2], -1.7 [-2.4 - -1.1] and -2.1 [-2.5 - -1.7]; all p<0.001), between negative antibody levels and PfHRP2 (-0.96 [-1.6 - -0.3]; p = 0.004) or Ptot (-1.1 [-1.2 - -0.3]; p = 0.009). Positive correlation was observed between positive antibody levels and Pcirc (0.5 [0.001-0.98]; p = 0.049). Pseq was positively correlated with the VSM group (6.5 [1.6-11.5]; p = 0.01) and was negatively cor- related with negative and positive antibody titer groups (-7.8 [-13.2 - -2.3] and -6.7 [-11.6 - -1.7]; both p<0.01) (Table 4).

<table><caption>Table 2. Repartition of antibody titer sub-groups in each epidemiological sub-group.</caption><thead><tr><th></th><th>FGM</th><th>SGM</th><th>T/E</th><th>P value*</th></tr></thead><tbody><tr><th scope="row">Antibody titer</th><td>No. (%)</td><td>No. (%)</td><td>No. (%)</td><td></td></tr><tr><th scope="row">Negative</th><td>39 (41.9)</td><td>23 (24.7)</td><td>31 (33.3)</td><td rowspan="2">&lt; 0.001</td></tr><tr><th scope="row">Positive</th><td>125 (69.8)</td><td>26 (14.5)</td><td>28 (15.6)</td></tr><tr><th scope="row">Strongly positive</th><td>47 (82.4)</td><td>3 (5.3)</td><td>7 (12.3)</td><td></td></tr></tbody></table>

FGM, first-generation migrants; SGM, second-generation migrants; T/E, Travelers/expatriates.

Patients with negative (<64), positive (between 64 and 1,024) and strongly positive antibody titers (superior or equal to 4,096), as determined by indirect immunofluorescence assay, are represented in percent (%) for each epidemiological sub-group.

(*) χ² and Fischer's exact test when appropriate were used to compare categorical variables between epidemiological sub-groups. Significant difference was considered when p<0.05.

https://doi.org/10.1371/journal.pone.0175328.t002

<table><caption>Table 3. Multivariate analysis with logistic regression to identify factors influencing positive serology at D0 in French imported malaria.</caption><thead><tr><th>Positive serology</th><th>Variable</th><th>Odds Ratio</th><th>[95% CI]</th><th>P value</th></tr></thead><tbody><tr><td></td><td>Age&lt;18 years</td><td>1.00 (reference group)</td><td></td><td></td></tr><tr><td></td><td>Age&gt;18 years</td><td>0.8</td><td>[0.3-2.2]</td><td>0.7</td></tr><tr><td></td><td>MSM</td><td>1.00 (reference group)</td><td></td><td></td></tr><tr><td></td><td>UM</td><td>2.2</td><td>[1.2-4]</td><td>0.008</td></tr><tr><td></td><td>VSM</td><td>2.1</td><td>[1-4.6]</td><td>0.06</td></tr><tr><td></td><td>FGM</td><td>1.00 (reference group)</td><td></td><td></td></tr><tr><td></td><td>SGM</td><td>0.3</td><td>[0.1-0.6]</td><td>0.002</td></tr><tr><td></td><td>T/E</td><td>0.3</td><td>[0.2-0.5]</td><td>&lt;0.001</td></tr></tbody></table>

VSM, very severe malaria; MSM, moderately severe malaria; UM, uncomplicated malaria; FGM, first-generation migrants; SGM, second-generation migrants; T/E, travelers/expatriates; CI, confidence interval.

Multivariate analysis was performed on 329 patients and age (as a binary variable: <18 years-old or >18 years-old), clinical sub-group (VSM, MSM, UM) and epidemiological sub-groups (FGM, SGM and T/E) were selected, as theoretical influent factors (age) or after univariate analysis (clinical and epidemiological sub-groups). Age< 18 years old, MSM and FGM were chosen as reference groups. Factors were considered to have a significant influence if p value<0.05.

https://doi.org/10.1371/journal.pone.0175328.t003
<table><caption>Table 4. Models of multivariate analysis with linear regression to identify factors related to PfHRP2, estimated total parasite biomass, estimated total circulating parasite biomass and estimated sequestered parasite biomass in imported malaria in France, 2010–2013.</caption><thead><tr><th>Model</th><th>Risk factors</th><th>Coefficient (standard error)</th><th>[95% CI]</th><th>P value</th></tr></thead><tbody><tr><td rowspan="8">Model 1: PfHRP2</td><td>Intercept</td><td>7 (0.44)</td><td>[6.1-7.9]</td><td>&lt; 0.0001</td></tr><tr><td>Age</td><td>0.0007 (0.008)</td><td>[-0.01-0.01]</td><td>0.93</td></tr><tr><td>Disease severity sub-groups</td><td></td><td></td><td></td></tr><tr><td>VSM</td><td>0.6 (0.3)</td><td>[-0.08-1.2]</td><td>0.09</td></tr><tr><td>UM</td><td>-1.6 (0.25)</td><td>[-2.1- -1.2]</td><td>&lt;0.001</td></tr><tr><td>Epidemiological sub-groups</td><td></td><td></td><td></td></tr><tr><td>SGM</td><td>0.4 (0.3)</td><td>[-0.3-1.1]</td><td>0.22</td></tr><tr><td>T/E</td><td>0.5 (0.3)</td><td>[-0.01-1.1]</td><td>0.06</td></tr><tr><td rowspan="12">Model 2: Ptot</td><td>Antibody titer sub-groups</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>-0.3 (0.3)</td><td>[-0.9-0.2]</td><td>0.23</td></tr><tr><td>Negative</td><td>-0.96 (0.3)</td><td>[-1.6- -0.3]</td><td>0.004</td></tr><tr><td>Intercept</td><td>28.5 (0.4)</td><td>[27.6-29.3]</td><td>&lt; 0.0001</td></tr><tr><td>Age</td><td>0.002 (0.01)</td><td>[-0.02-0.02]</td><td>0.83</td></tr><tr><td>Disease severity sub-groups</td><td></td><td></td><td></td></tr><tr><td>VSM</td><td>0.5 (0.4)</td><td>[-0.3-1.2]</td><td>0.23</td></tr><tr><td>UM</td><td>-1.7 (0.3)</td><td>[-2.4- -1.1]</td><td>&lt;0.001</td></tr><tr><td>Epidemiological sub-groups</td><td></td><td></td><td></td></tr><tr><td>SGM</td><td>-0.3 (0.4)</td><td>[-1.2-0.6]</td><td>0.52</td></tr><tr><td>T/E</td><td>0.3 (0.4)</td><td>[-0.5-1.0]</td><td>0.48</td></tr><tr><td>Antibody titer sub-groups</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>-0.7 (0.4)</td><td>[-1.5-0.07]</td><td>0.08</td></tr><tr><td>Negative</td><td>-1.1 (0.4)</td><td>[-2.0- -0.3]</td><td>0.009</td></tr><tr><td rowspan="8">Model 3: Pcirc</td><td>Intercept</td><td>26.5 (0.3)</td><td>[25.9-27.1]</td><td>&lt; 0.0001</td></tr><tr><td>Age</td><td>0.02 (0.01)</td><td>[0.004-0.03]</td><td>0.01</td></tr><tr><td>Disease severity sub-groups</td><td></td><td></td><td></td></tr><tr><td>VSM</td><td>-0.1 (0.2)</td><td>[-0.6-0.3]</td><td>0.55</td></tr><tr><td>UM</td><td>-2.1 (0.2)</td><td>[-2.5- -1.7]</td><td>&lt;0.001</td></tr><tr><td>Epidemiological sub-groups</td><td></td><td></td><td></td></tr><tr><td>SGM</td><td>-0.3 (0.3)</td><td>[-0.9-0.22]</td><td>0.23</td></tr><tr><td>T/E</td><td>0.1 (0.2)</td><td>[-0.3-0.6]</td><td>0.61</td></tr><tr><td rowspan="12">Model 4: Pseq</td><td>Antibody titer sub-groups</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>0.5 (0.2)</td><td>[0.001-0.98]</td><td>0.049</td></tr><tr><td>Negative</td><td>0.5 (0.3)</td><td>[-0.006-1.1]</td><td>0.052</td></tr><tr><td>Intercept</td><td>26.5 (2.9)</td><td>[21-32.2]</td><td>&lt; 0.0001</td></tr><tr><td>Age</td><td>-0.08 (0.07)</td><td>[-0.2-0.05]</td><td>0.23</td></tr><tr><td>Disease severity sub-groups</td><td></td><td></td><td></td></tr><tr><td>VSM</td><td>6.5 (2.5)</td><td>[1.6-11.5]</td><td>0.01</td></tr><tr><td>UM</td><td>1.2 (2.1)</td><td>[-2.9-5.2]</td><td>0.6</td></tr><tr><td>Epidemiological sub-groups</td><td></td><td></td><td></td></tr><tr><td>SGM</td><td>-0.4 (2.9)</td><td>[-6.0-5.3]</td><td>0.9</td></tr><tr><td>T/E</td><td>1.9 (2.4)</td><td>[-2.8-6.6]</td><td>0.42</td></tr><tr><td>Antibody titer sub-groups</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>-6.7 (2.5)</td><td>[-11.6- -1.7]</td><td>0.009</td></tr><tr><td>Negative</td><td>-7.8 (2.8)</td><td>[-13.2- -2.3]</td><td>0.005</td></tr></tbody></table>

VSM, very severe malaria; MSM, moderately severe malaria; UM, uncomplicated malaria; FGM, first-generation migrants; SGM, second-generation migrants; T/E, travelers/expatriates; CI, confidence interval.

A linear regression was performed on 315 patients for PfHRP2 and on 176 patients for Ptot, Pcirc and Pseq. Age, disease severity sub-group (VSM, MSM, UM), epidemiological sub-group (FGM, SGM, T/E) and antibody titer sub-groups (negative, positive, strongly positive) were selected as potential factors after univariate analysis. MSM, FGM and strongly positive antibody titer sub-groups were chosen as reference. PfHRP2, Ptot, Pcirc, Pseq were log-transformed for statistical analysis. Significance was set to p<0.05.

https://doi.org/10.1371/journal.pone.0175328.t004
Discussion

A wide variety of clinical presentation could be seen in the context of imported malaria. Through the CNRP network and database, the study of imported severe and non-severe malaria cases, as defined by the WHO criteria established in 2000 and still in force in France, reaffirmed since 2013 [23] despite the 2014 WHO criteria [24], allowed us to identify risk factors in susceptible populations.

As reported previously, severe malaria patients, and particularly very severe malaria patients, are older than uncomplicated malaria patients [2, 16, 25], and differ in ethnicity [3, 16, 18], delay between onset of symptoms and diagnosis [18], previous history of malaria [16] and thrombocytopenia [26]. High parasite density is more frequent in SM, but similar in very severe malaria and moderately severe malaria patients. Among epidemiological sub-groups with a risk factor in severe malaria, travelers/expatriates are most susceptible to very severe malaria. Multivariate analysis including all these significant variables confirmed a significant association between age, serological status at D0 and severe imported malaria onset. Serological status is theoretically correlated with pre exposure to malaria and also associated with epidemiological sub-groups (second-generation migrants and travelers/expatriates) and disease severity sub-groups (UM) as observed in multivariate analysis. Compared to 70.4% in the uncomplicated malaria group which reported prior history of malaria, absence of or low prior exposure to *P. falciparum* in travelers/expatriates may explain this difference in clinical presentation. The high rate of prior history of malaria reported in 73.2% in the first-generation migrants groups corroborated our observations. Accordingly, it may be hypothesized that the potential protective effect of prior exposure to *P. falciparum* against SM, likely depends on the frequency and number of prior exposures [12, 27, 28]. Antibody detection and titers are informative with regard to prior exposure to *Plasmodium* spp. but not with regard to anti-malarial immune protection, providing quantitative but not qualitative information on the antibody response. The hypothesis of probable long-term protection in first-generation migrants is consistent with our results [29]. Persistence of protection after leaving malaria-endemic areas has already been suggested, but few biological data on immune responses are available [29, 30]. However, the differences in clinical presentation, observed in second-generation migrants and travelers/expatriates suggest the possibility that other factors are involved in protection against SM [31, 32]. Moreover, the difference in antibody response between first-generation migrants and second-generation migrants may also result from differences in exposure to the parasite.

Plasma PfHRP2 concentrations, Ptot and Pcirc correlated with the severity of malaria infection as observed in univariate and multivariate statistical analysis, but did not differentiate severe forms [14, 33]. Mathematical modeling to calculate parasite biomass may require taking into account both the *P. falciparum* strain and the population studied, which are thus central factors in this limitation, as already discussed by Dondorp et al., [14]. However, the lack of power or other pathophysiological mechanisms may also impede the detection of differences between SM sub-groups [14]. As we used the same methodology to estimate parasite biomass, this bias likely also applies to our work. As described by Cunnington et al., [34] sequestered parasite biomass is similar between SM and UM, confirming that parasite sequestration also occurs in UM. Distinct adhesion phenotypes may explain differences in malaria pathogenesis and in clinical presentation [11]. High antibody levels probably limit sequestration in UM, or favor an adhesion phenotype switch. However, linear regression model revealed a strong interaction between sequestered parasite biomass and VSM confirming a key role of the sequestration in very severe malaria. As observed for PfHRP2, Ptot and Pcirc, significant correlation between Pseq and the host antibody response was also observed, revealing interaction between parasite biomass and antibodies response.
Our study utilizing the CNRP network is subject to limitations. Recording of imported malaria cases is estimated to be 52% complete, and the percentage of sample transfer after notification was 75.8% in 2014, leading to a possible underestimation of particular clinical presentations as cerebral malaria [35]. Moreover, inclusion criteria with negative drug plasma levels to avoid the influence of drugs on biological data have limited the number of patients included, as antimalarial self-medication was frequently detected. Non-exhaustive information is sufficient for notification of imported malaria cases to the CNRP database, meaning that specific data may be missing, eventually preventing calculation of the parasite biomass. Determination of PfHRP2 was not performed if sample volume was inadequate. Pediatric cases were not included in our study because of insufficient blood sample volume, leading to skewed recruitment of children.

Our study of imported malaria confirms that ethnic origin, and anti-*P. falciparum* antibody response, correlated to prior exposure to *P. falciparum*, influent the clinical presentation of imported malaria. Parasite biomass may also determine the nature of the clinical presentation and significantly interact with antibodies titers. Our data suggest the key role of prior exposure to *P. falciparum* in inducing protection against VSM, generating antibody levels which significantly reduce the circulating and sequestered parasite burden. A more accurate qualitative study of the protective antibody repertoire is needed to understand the host-parasite interactions in non-exposed patients in imported malaria context.

**Supporting information**

**S1 Table. Correlation matrix between plasmatic HRP2, estimated total parasite biomass, estimated total circulating parasite biomass and estimated sequestered parasite biomass.**
Ptot, estimated total parasite biomass; Pcirc, estimated total circulating parasite biomass; Pseq, estimated sequestered parasite biomass.
(DOCX)

**S2 Table. Models of multivariate analysis with logistic regression to identify factors influencing very severe malaria onset in French imported malaria.** FGM, first-generation of migrants; SGM, Second-generation of migrants; T/E, Travellers/expatriates; VSM, very severe malaria; CI, Confidence interval; Ptot, estimated total parasite biomass; Pcirc, estimated total circulating biomass; Pseq, estimated sequestered parasite biomass. Multivariate analysis was performed on 315 patients for PfHRP2 (model 1) and 176 patients for Ptot, Pcirc and Pseq (model 2-4 respectively). Age, malaria exposure, serology status and log-transformed PfHRP2, Ptot, Pcirc and Pseq were selected, considered as influent factors. FGM and strongly positive serology were chosen as reference group for the analysis whereas age, PfHRP2, Ptot, Pcirc and Pseq were considered as continuous variable. Factors have a significant influence if p value<0.05.
(DOCX)

**S3 Table. Models of multivariate analysis with logistic regression to identify factors influencing moderately severe malaria onset in French imported malaria.** FGM, first-generation of migrants; SGM, Second-generation of migrants; T/E, Travellers/expatriates; VSM, very severe malaria; CI, Confidence interval; Ptot, estimated total parasite biomass; Pcirc, estimated total circulating biomass; Pseq, estimated sequestered parasite biomass. Multivariate analysis was performed on 315 patients for PfHRP2 (model 1) and 176 patients for Ptot, Pcirc and Pseq (model 2-4 respectively). Age, malaria exposure, serology status and log-transformed PfHRP2, Ptot, Pcirc and Pseq were selected, considered as influent factors. FGM and strongly positive serology were chosen as reference group for the analysis whereas age, PfHRP2, Ptot,
Pcirc and Pseq were considered as continuous variable. Factors have a significant influence if p value<0.05.
(DOCX)

**S4 Table. Models of multivariate analysis with logistic regression to identify factors influencing uncomplicated malaria onset in French imported malaria.** FGM, first-generation of migrants; SGM, Second-generation of migrants; T/E, Travellers/expatriates; VSM, very severe malaria; CI, Confidence interval; Ptot, estimated total parasite biomass; Pcirc, estimated total circulating biomass; Pseq, estimated sequestered parasite biomass. Multivariate analysis was performed on 315 patients for PfHRP2 (model 1) and 176 patients for Ptot, Pcirc and Pseq (model 2–4 respectively). Age, malaria exposure, serology status and log-transformed PfHRP2, Ptot, Pcirc and Pseq were selected, considered as influent factors. FGM and strongly positive serology were chosen as reference group for the analysis whereas age, PfHRP2, Ptot, Pcirc and Pseq were considered as continuous variable. Factors have a significant influence if p value<0.05.
(DOCX)

**Acknowledgments**

We thank additional members of the CNRP study group for their contribution to the collection of data:

Sophie Matheron* (Service des maladies infectieuses et tropicales, Hôpital Bichat-Claude Bernard, APHP, Paris, France); Enrique Casalino (Service des urgences, Hôpital Bichat-Claude Bernard, APHP, Paris, France); Michel Wolff (Service de réanimation médicale, Hôpital Bichat-Claude Bernard, APHP, Paris, France); Anne Delaval (Laboratoire de parasitologie-mycologie, Hôpital Robert Ballanger, Aulnay-sous-bois, France); Patrice Agnamey (Laboratoire de parasitologie-mycologie, CHU Amiens, Amiens, France); Rémi Durand (Laboratoire de parasitologie-mycologie, CHU Avicenne, APHP, Bobigny, France); Jean Etienne Pilo (Laboratoire de biologie, HIA Begin, Sant-Mandé, France); Christophe Rapp (Service des maladies infectieuses, HIA Begin, Sant-Mandé, France); Jean François Faucher (Service des maladies infectieuses, CHU Besançon, Besançon, France); Bernadette Cuisenier (Laboratoire de parasitologie-mycologie, CHU Dijon, Dijon, France); Isabelle Poilane and Dieudonné Bemba (Laboratoire de microbiologie, CHU Jean Verdier, Bondy, France); Aurélie Roide (Laboratoire d'hématologie, CHU Lariboisière, APHP, Paris, France); Anne Debourgogne (Laboratoire de parasitologie-mycologie, CHU Nancy, Nancy, France); Michel Thibault (Laboratoire de microbiologie, Hôpital René Dubos, Pontoise, France); Dominique Toubas (Laboratoire de parasitologie-mycologie, CHU Reims, Reims, France); Pierre Patoz (Laboratoire de parasitologie, CH Tourcoing, Tourcoing, France); Ludovic De Gentile (Laboratoire de parasitologie-mycologie, CHU Angers, Angers, France); Dominique Pons (Laboratoire de parasitologie-mycologie, CHU Clermont-Ferrand, Clermond-Ferrand, France); Jean Pierre Hurst (Laboratoire d'hématologie, CH Jacques Monod, Le Havre, France); Caroline Lohmann (Laboratoire de microbiologie, CH Mulhouse, Mulhouse, France); Marie Laure Bigel (Laboratoire de microbiologie, CH Mantes-la-Jolie, Mantes-la-Jolie, France); Nadine Godineau (Laboratoire de microbiologie, Hôpital Delafontaine, Saint-Denis, France); Maxime Thouvenin (Laboratoire de microbiologie, CH Troyes, Troyes, France); Jean Dunand and Nawel Ait-Ammar (Laboratoire de parasitologie-mycologie, CHU Ambroise Paré, APHP, Boulogne-Billancourt, France); Adela Angoulvant (Laboratoire de parasitologie-mycologie, CHU du Kremlin-Bicêtre, Le Kremlin-Bicêtre, France); Naima Dahane (Laboratoire de parasitologie-mycologie, CHU Cochin, APHP, Paris, France); Magali Lefevre (Laboratoire de biologie médicale, GH
Public du Sud de l'Oise, Creil, France); Jean Benjamin Murat and Cécile Garnaud (Laboratoire de parasitologie-mycologie, CHU Grenoble, Grenoble, France); Eric Dannaoui (Laboratoire de parasitologie-mycologie, Hôpital Européen Georges Pompidou, APHP, Paris, France); Françoise Botterel (Laboratoire de parasitologie-mycologie, CHU Henri Mondor, APHP, Créteil, France); Emmanuel Dutoit (Laboratoire de parasitologie-mycologie, CHRU Lille, Lille, France); Marie Laure Dardé (Laboratoire de parasitologie-mycologie, CHU Dupuytren, Limoges, France); Houria Ichou and Catherine Branger (Laboratoire de microbiologie, CHU Louis Mourier, APHP, Colombes, France); Pascal Penn (Laboratoire de biologie, CH Le Mans, Le Mans, France); Cécile Angebault (Laboratoire de parasitologie-mycologie, CHU Necker, APHP, Paris, France); Florient Morio (Laboratoire de parasitologie-mycologie, CHU Nantes, Nantes, France); Laurent Bret (Laboratoire de parasitologie-mycologie, CHR Orléans, Oussama Mouri (Laboratoire de parasitologie-mycologie, CHU Pitié-Salpétrière, APHP, Paris, France); Estelle Cateau (Laboratoire de parasitologie-mycologie, CHU Poitiers, Poitiers, France); Jean Yves Siriez (Service des urgences pédiatriques, CHU Robert Debré, APHP, Paris, France); O. Fenneteau (Laboratoire d'hémaotologie, CHU Robert Debré, APHP, Paris, France); Mathieu Revest (Service des maladies infectieuses, CHU Pontchaillou, rennes, France); Soria Belaz (Laboratoire de parasitologie-mycologie, CHU Pontchaillou, rennes, France); Ghania Belkadi (Laboratoire de parasitologie-mycologie, CHU Saint Antoine, APHP, Paris, France); Samia Hamane and Stéphane Bretagne (Laboratoire de parasitologie-mycologie, CHU Saint Louis, APHP, Paris, France); Ahmed Aboubacar (Laboratoire de parasitologie-mycologie, CHU Strasbourg, Strasbourg, France); Guillaume Leloup (Service des maladies infectieuses, CHU Tenon, APHP, Paris, France); Michel Develoux (Laboratoire de parasitologie-mycologie, CHU Tenon, APHP, Paris, France); Hélène Lapillonne (Laboratoire d'hématologie, CHU Armand Trousseau, APHP, Paris, France); Odile Eloy (Laboratoire de microbiologie, CHU André Mignot, Le Chesnay, France); Gilles Nevez (Laboratoire de parasitologie-mycologie, CHU Brest, Brest, France); Didier Raffenot (Laboratoire de microbiologie, CHU Chambéry, Chambéry, France), Bernadette Buret (Laboratoire de biologie, CH Niort, Niort, France), Guillaume Desoubeaux (Laboratoire de parasitologie-mycologie, CHRU Bretonneau, Tours, France), and Anne Goepp (Laboratoire de microbiologie, CH Villeneuve Saint-Georges, Villeneuve Saint-Georges, France).

* Contact email address of the lead author: sophie.matheron@aphp.fr

We thank Vincent Samson, Florianne Ferreira, Maribel Rodriguez-Gutierrez and Camille Moisant for technical support and Michel Cot for the manuscript revision.

## Author Contributions

**Conceptualization:** SH PD JC SC NA MT.

**Data curation:** NA EK CAC PH VH CNRP.

**Formal analysis:** NA EK.

**Funding acquisition:** SH.

**Investigation:** NA VH SH MT.

**Methodology:** NA EK.

**Project administration:** MT SH PD.

**Resources:** SH PD.

**Software:** EK.
**Supervision:** SH, PD.

**Validation:** NA EK SC JC PD SH.

**Visualization:** NA EK PD SH.

**Writing – original draft:** NA EK SH PD JC.

**Writing – review & editing:** SH PD JC SC.

## References

1. European Centre for disease prevention and control. Annual epidemiological report. 2014.

2. Bruneel F, Hocqueloux L, Alberti C, Wolff M, Chevret S, Bédos JP et al. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med. 2003; 167:684–89. https://doi.org/10.1164/rccm.200206-631OC PMID: 12411286

3. Bruneel F, Tubach F, Corne P, Megarbane B, Mira JP, Peytel E et al. Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS ONE. 2010; 5:e13236. https://doi.org/10.1371/journal.pone.0013236 PMID: 20949045

4. Marks ME, Armstrong M, Suvari MM, Batson S, Whitty CJ, Chiodini PL et al. Severe imported falciparum malaria among adults requiring intensive care: a retrospective study at the hospital for tropical diseases, London. BMC Infect Dis. 2013; 13:118. https://doi.org/10.1186/1471-2334-13-118 PMID: 23497139

5. González A, Nicolás JM, Muñoz J, Castro P, Mas J, Valls ME et al. Severe imported malaria in adults: retrospective study of 20 cases. Am J Trop Med Hyg. 2009; 81:595–99. https://doi.org/10.4269/ajtmh.2009.08-0637 PMID: 19815872

6. Marchiafava E, Bignami A. On summer-autumn malarial fevers. In: Marchiafava E, editors. Two monographs on malaria and the parasites of malarial fevers. London: New Sydenham Society; 1894. pp. 1–232.

7. Hanson J, Lee SJ, Hossain MA, Anstey NM, Charunwatthana P, Maude RJ et al. Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study. BMC Med. 2015; 13:122. https://doi.org/10.1186/s12916-015-0365-9 PMID: 26018532

8. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol. 1985; 119:385–401. PMID: 3893148

9. Turner GD, Morrisson H, Jones M, Davis TM, Looareesuwan S, Buley ID et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol. 1994; 145:1057–69. PMID: 7526692

10. Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol Med. 2009; 11:e16. https://doi.org/10.1017/S1462399409001082 PMID: 19467172

11. Smith JD, Rowe JA, Higgins MK, Lavstsen T. Malaria's deadly grip: cytoadhesion of Plasmodium falciparum-infected erythrocytes. Cell Microbiol. 2013; 15:1976–83. https://doi.org/10.1111/cmi.12183 PMID: 23957661

12. Doolan DL, Dobaño C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009; 22:13–36. https://doi.org/10.1128/CMR.00025-08 PMID: 19136431

13. Rubach MP, Mukemba J, Florence S, John B, Crookston B, Lopansri BK et al. Plasma Plasmodium falciparum histidine-rich protein-2 concentrations are associated with malaria severity and mortality in Tanzanian children. PLoS ONE. 2012; 7:e35985. https://doi.org/10.1371/journal.pone.0035985 PMID: 22586457

14. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 2005; 2:e204. https://doi.org/10.1371/journal.pmed.0020204 PMID: 16104831

15. Hendriksen ICE, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med. 2012; 9:e1001297. https://doi.org/10.1371/journal.pmed.1001297 PMID: 22927801
16. Phillips A, Bassett P, Zeki S, Newman S, Pasvol G. Risk factors for severe disease in adults with falciparum malaria. Clin Infect Dis. 2009; 48:871-78. https://doi.org/10.1086/597258 PMID: 19243243

17. Checkley AM, Smith A, Smith V, Blaze M, Bradley D, Chiodini PL, Whitty CJM. Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ. 2012; 344:e2116. https://doi.org/10.1136/bmj.e2116 PMID: 22454091

18. Seringe E, Thellier M, Fontanet A, Legros F, Bouchaud O, Ancelle T et al. Severe imported Plasmodium falciparum malaria, France, 1996–2003. Emer Infect Dis. 2011; 17:807–13. https://doi.org/10.3201/eid1705.101527 PMID: 21529388

19. Société de Pathologie Infectieuse de Langue Française, Collège des Universitaires de Maladies Infectionuses et Tropicales, Société Française de Médecine des Armées, Société Française de Parasitologie, Société Française de Pédiatrie, Société de Médecine des Voyages, Société de Pathologie Exotique, and Société de Réanimation de Langue Française. Management and prevention of imported Plasmodium falciparum malaria (Revision 2007 of the 1999 Consensus Conference). Médecine Mal Infect. 2008; 38:68–117.

20. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol. 1993; 58:283-92. PMID: 8479452

21. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993; 61:315-20. PMID: 8264734

22. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000; 94:S1-90. PMID: 11103309

23. Haut Conseil de la santé publique. Place de l'artésunate injectable dans le traitement du paludisme grave de l'adulte et de l'enfant. from: http://www.hcsp.fr.

24. World Health Organization. Guidelines for the treatment of malaria, third edition 2015. from: http://www.who.int.

25. Mühlberger N, Jelinek T, Behrens RH, Gjorup I, Coulaud JP, Clerinx J et al. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis. 2003; 36:990-95. https://doi.org/10.1086/374224 PMID: 12684911

26. Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D et al. Severe Malarial Thrombocytopenia: A Risk Factor for Mortality in Papua, Indonesia. J Infect Dis. 2014; 211:623-34. https://doi.org/10.1093/infdis/jiu487 PMID: 25170106

27. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med. 1999; 5:340-43. https://doi.org/10.1038/6560 PMID: 10086393

28. Kurtis JD, Mtalib R, Onyango FK, Duffy PE. Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels. Infect Immun. 2001; 69:123-28. https://doi.org/10.1128/IAI.69.1.123-128.2001 PMID: 11119497

29. Bouchaud O, Cot M, Kony S, Durand R, Schiemann R, Ralaimazava P et al. Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg. 2005; 72:21-25. PMID: 15728861

30. Ndungu FM, Lundblom K, Rono J, Illingworth J, Eriksson S, Färnert A. Long-lived Plasmodium falciparum specific memory B cells in naturally exposed Swedish travelers. Eur J Immunol. 2013; 43:2919-29. https://doi.org/10.1002/eji.201343630 PMID: 23881859

31. Cseri-Gazdewich CM, Mayr WR, Dzik WH. Plasmodium falciparum malaria and the immunogenetics of ABO, HLA, and CD36 (platelet glycoprotein IV). Vox Sang. 2011; 100:99-111. https://doi.org/10.1111/j.1423-0410.2010.01429.x PMID: 21175660

32. Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathog. 2013; e1003327. https://doi.org/10.1371/journal.ppat.1003327 PMID: 23696730

33. Gonçalves BP, Huang CY, Morrison R, Holte S, Kabyemela E, Prevots DR et al. Parasite burden and severity of malaria in Tanzanian children. N Engl J Med. 2014; 370:1799-1808. https://doi.org/10.1056/NEJMoa1303944 PMID: 24806160

34. Cunningham AJ, Bretscher MT, Nogaro SI, Riley EM, Walther M. Comparison of parasite sequestration in uncomplicated and severe childhood Plasmodium falciparum malaria. J Infect. 2013; 67:220-30. https://doi.org/10.1016/j.jinf.2013.04.013 PMID: 23623771

35. Centre National de Référence du Paludisme pour la France métropolitaine. Rapport annuel 2015. http://www.cnrpalu-france.org/pages/rapports-annuels/.